RUN-20260715-600276-20260715045841549715-a06a368e
股票 600276 恒瑞医药 ｜ 模型 deepseek-v4-pro ｜ 状态 started ｜ 结论
运行载荷
{
"candidate": {
"date": "2026-07-15",
"market": "main_board",
"score": 30.23,
"score_max": 60,
"setup": "LOW_VOLUME_BREAKOUT",
"status": "OBSERVE",
"stock_code": "600276",
"stock_name": "恒瑞医药",
"theme": "创新药",
"theme_score": 35.2,
"theme_stage": "发酵",
"veto_reasons": []
},
"evidence_ids": [
"EVD-077cf2a882da8a0f",
"EVD-1633902c6cbba5e7",
"EVD-24de1c4a19c43ad4",
"EVD-3ca8534cc7f3d4f4",
"EVD-67db64ca05505bb3",
"EVD-bed1cd27fcbe95a1",
"EVD-bf4e7a9e2d77f70e",
"EVD-cdaf22fff6eef444"
]
}节点记录
| 角色 | 状态 | 得分 | 上限 | 结论 | 时间 |
|---|---|---|---|---|---|
| technical | completed | 6.5 | 8 | 技术面呈现放量突破态势，短期趋势强劲，但中期角度仍处于震荡区间上沿，突破有效性有待进一步确认。 | 2026-07-15 04:59:04 |
| sentiment | completed | 4 | 4 | 情绪维度积极，创新药主题处于发酵阶段，板块交投活跃，个股成交额位居前列，新闻催化密集，市场资金关注度高。 | 2026-07-15 04:59:20 |
| news | completed | 4 | 5 | 当日创新药板块整体活跃，政策支持及BD交易活跃构成情绪支撑，但恒瑞医药自身无直接重大新闻，涨势更多受板块带动，消息面中性偏积极。 | 2026-07-15 04:59:52 |
| fundamentals | completed | 5 | 5 | 恒瑞医药基本面优异，盈利能力强劲，负债水平低，现金流充裕 | 2026-07-15 05:00:08 |
| policy | completed | 2 | 5 | 政策面暂时缺乏直接催化事件，但创新药行业整体受益于'十五五'规划等长期支持。 | 2026-07-15 05:00:16 |
| hot_money | completed | 1 | 5 | 根据当日龙虎榜数据，恒瑞医药未上榜，游资参与迹象缺失，表明短期内游资对该股关注度较低。 | 2026-07-15 05:00:31 |
| lockup | completed | 4 | 4 | 未来90日内无解禁压力，流动性风险极低。 | 2026-07-15 05:00:38 |
| research | completed | 4 | 4 | 多家卖方机构一致看好，给予“买入”评级，盈利预测乐观，创新成果加速落地，国际化战略持续推进，无负面信号。 | 2026-07-15 05:00:48 |
| bull_researcher | completed | 0 | 0 | completed | 2026-07-15 05:01:10 |
| bear_researcher | completed | 0 | 0 | completed | 2026-07-15 05:01:37 |
| risk_manager | completed | -5 | 0 | 恒瑞医药(600276)基本面优异，创新药主题发酵，机构一致看好，但技术面低量突破有效性待验证，中期趋势偏弱，游资参与缺失，个股缺乏直接催化，且大盘环境一般，存在突破失败和主题退潮风险。 | 2026-07-15 05:01:50 |